☰
×
News
Top 20
Insights
Insights+
ThoughtSpot
Interviews
Viewpoints
Exclusive
Spotlight
Events
Magazine
Bespoke
Newswire
x
Search
Search here
Search here
Subscribe Now
dupixent
Sanofi Reports Results of Dupixent (dupilumab) in P-III LIBERTY ASTHMA VOYAGE Study in Children with Asthma
October 13, 2020
Sanofi's Dupixent Receives the US FDA's Breakthrough Therapy Designation for Eosinophilic Esophagitis
September 14, 2020
Sanofi Reports Results of Dupixent (dupilumab) in P-III LIBERTY ASTHMA TRAVERSE OLE Study for Asthma
September 8, 2020
Sanofi's Dupixent (dupilumab) Receives the Health Canada Approval for Severe Chronic Rhinosinusitis with Nasal Polyposis
August 19, 2020
Load more...
Back to Home
Modal title
×
Modal body text goes here.